There are currently 623 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Children's Medical Center of Central Texas, Pfizer Investigational Site and DermResearch Inc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Non-invasive BCI-controlled Assistive Devices
NCT05183152
Recruiting
A brain-computer interface (BCI) decodes users' behavioral intentions or mental states directly from their brain activity, thus allowing operation of devices without requiring any overt motor action. One major modality for BCI control is based on motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. MI-based BCIs translate motor intents into control commands for external devices. A major challenge in such BCIs is differentiating MI pa... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
12/01/2022
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders
Register for Updates
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
NCT05467683
Recruiting
Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/02/2022
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Register for Updates
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
NCT05280717
Recruiting
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy participants aged 18 to 65 years. The study will be conducted in three parts (Part A, an optional Part B and Part C).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/02/2022
Locations: Investigative Site, Austin, Texas
Conditions: Covid19
Register for Updates
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
NCT04160000
Recruiting
Heart failure (HF) with preserved left ventricular function (pEF) is difficult clinical syndrome to treat effectively with few evidence based therapies. Atrial fibrillation (AF) is now an important co-morbidity being observed in 43% of patients with HFpEF. Rhythm control has not been studied in this population. Catheter ablation and antiarrhythmic drugs are rhythm control therapies that have been used for treatment of AF without HF or HF with reduced systolic function but have not been widely ap... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/18/2022
Locations: TCAI at St. David's Hospital, Austin, Texas
Conditions: Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Register for Updates
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
NCT03477604
Recruiting
Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/03/2022
Locations: Cardiothoracic and Vascular Surgeons, Austin, Texas
Conditions: Peripheral Arterial Disease
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: American Research Corporation, Austin, Texas +1 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
NCT04893486
Recruiting
A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 mon... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/26/2022
Locations: DermResearch Inc, Austin, Texas
Conditions: BCCs in Gorlin Syndrome Patients
Register for Updates
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
NCT05180708
Recruiting
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/26/2022
Locations: DermResearch, Inc., Austin, Texas
Conditions: Pachyonychia Congenita
Register for Updates
GamePlan4Care: Online Support for Family Caregivers
NCT04540198
Recruiting
As the population of older adults grows, almost doubling in size from 2012 to 2040, so too will the need for family caregiving. Caregiving can lead to negative psychosocial outcomes such as depression, anxiety, and burden; social isolation and family conflict: financial strain due to costs of care; and some caregivers also experience negative health consequences. This project will test the value of GamePlan4Care (GP4C) an evidence-based, internet-enabled system capable of providing immediate, ta... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2022
Locations: Alzheimer's Texas, Austin, Texas
Conditions: Dementia
Register for Updates
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357
Recruiting
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Keystone Research, Austin, Texas
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates
A Study in Patients With Advanced Cancers
NCT05320588
Recruiting
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/15/2022
Locations: NEXT Oncology Austin, Austin, Texas
Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Register for Updates
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
NCT04976595
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: North Austin Urology, Austin, Texas
Conditions: Hypogonadism
Register for Updates